Rivaroxaban reduces stent thrombosis risk, study says

04/19/2013 | MedPage Today (free registration)

Adding the anticoagulant rivaroxaban to dual antiplatelet therapy decreased the chances of death and stent thrombosis among patients being treated for acute coronary syndrome, according to a study in the Journal of the American College of Cardiology. The findings were based on an analysis of a 9,631-patient subgroup of the ATLAS ACS 2-TIMI 51 trial.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA